Immunocore Appoints Paul Fry as Chief Financial Officer

12 October 2016 at 11:00 AM EDT

(Oxford, UK, 12 October 2016) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces the appointment of Paul Fry as Chief Financial Officer.

Paul joins Immunocore with over 20 years’ experience in senior positions in the life sciences and telecommunications sectors. Prior to joining Immunocore he served as Director of Global Finance Operations at Vodafone Plc, where he was responsible for key financial controllership activities, core processes as well as large transformation projects and programmes.

Prior to joining Vodafone, Paul spent more than 25 years at GlaxoSmithKline, serving in a number of roles including Head of Global Finance Services and as CFO for GSK’s Italian Pharmaceutical business. More recently he oversaw all of the financial aspects of the multibillion dollar transaction which saw GSK divest its oncology business in a transfer for Novartis Vaccines.  

Paul enters Immunocore at a time when it is expanding its proprietary pipeline of soluble, TCR based, biological drugs, further developing its strategic pharmaceutical partnerships and bolstering its growing clinical, commercial and regulatory infrastructure both in the UK and the US. 

Commenting on the appointment, Dr Eliot Forster, Chief Executive Officer of Immunocore, said: “I am delighted that Immunocore has been able to recruit someone of the calibre of Paul Fry, who will provide leadership across our financial operations as we continue our mission to become a world leader in biotechnology. As Immunocore continues to grow we are continually looking for outstanding individuals such as Paul to complement our team. He joins at an exciting time for the Company, and we very much look forward to working with him.”

Paul Fry commented: “Immunocore is one of the most dynamic companies in the life sciences sector and, in the wake of its successful $320 million private financing round, is in a great position to build its portfolio of TCR based drugs into a successful, integrated pharmaceutical company. I am very excited to begin working with the team.”

Please click on the link below to download the full Press Release: